Edgewise Therapeutics, Inc. (EWTX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
Edgewise Therapeutics remains a "Buy," driven by pipeline focus and a transformative $2.65B sale of its muscular dystrophy program to Servier. Company will use the $1.55B upfront cash to fully fund EDG-7500 development for oHCM/nHCM, targeting pivotal phase 3 initiation in Q4 2026. Topline 12-week Part D data from the phase 2 CIRRUS-HCM study for EDG-7500 is expected in Q2 2026, a key catalyst for advancing to phase 3.
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
EWTX surges 18% to a record high after striking a $2.65 billion neuromuscular business divestiture deal with Servier, sharpening focus on its cardiovascular pipeline.
Edgewise Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 135 | $2,832.5 | $5,372.97 | $2,540.47 | 89.69% |
| BG Bart Gancher Intech Investment Management LLC | 18,480 | $437,730.4 | $732,732 | $295,001.6 | 67.39% |
 John H. Burbank III Passport Capital LLC | 6.58M | $97.66M | $260.74M | $163.08M | 166.99% |
 Didric Cederholm Lion Point Capital LP | 9,100 | $225,817 | $360,815 | $134,998 | 59.78% |
 David Kim Paradigm Biocapital Advisors LP | 7.37M | $157.02M | $294.1M | $137.08M | 87.3% |
Edgewise Therapeutics, Inc. (EWTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Edgewise Therapeutics, Inc. ever had a stock split?
Edgewise Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Kevin Koch CEO | NASDAQ (NGS) Exchange | 28036F105 CUSIP |
| US Country | 154 Employees | - Last Dividend | - Last Split | 26 Mar 2021 IPO Date |
Overview
Edgewise Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for muscle disorders. Established in 2017, the company focuses on addressing the root causes of these conditions through the development of small molecule therapies. Situated in Boulder, Colorado, Edgewise Therapeutics leverages precision medicine to target key muscle proteins and modulators, aiming to provide effective treatments for patients with genetically defined muscle disorders.
Products and Services
EDG-5506 - This leading product candidate is an orally administered small molecule, currently in Phase II clinical trials. It is designed specifically to tackle the underlying causes of dystrophinopathies, such as Duchenne muscular dystrophy and Becker muscular dystrophy. By focusing on these root issues, EDG-5506 aims to offer a significant advancement in the treatment of these debilitating muscle disorders.
EDG-7500 - Another key development in their portfolio, EDG-7500 is a small molecule aimed at the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. Currently in Phase I clinical trials, this novel therapy represents Edgewise Therapeutics’ commitment to extending its reach beyond muscle disorders to address severe cardiac conditions with precision medicine approaches.
In addition to these leading candidates, Edgewise Therapeutics is working on developing a pipeline of precision medicine product candidates. These are targeted at key muscle proteins and modulators to tackle genetically defined muscle disorders comprehensively. Through these efforts, Edgewise Therapeutics aims to broaden its impact in treating muscle-related conditions, emphasizing the potential for advancements in therapeutics tailored to specific genetic profiles.
